Blockade of striatal dopamine transporters by intravenous methylphenidate is not sufficient to induce self-reports of 'high'

Journal of Pharmacology and Experimental Therapeutics

Volumn 288, Issue 1, 1999, Pages 14-20

  Volkow, Nora D ^a,b   Wang, Gene Jack ^a   Fowler, Joanna S ^a   Gatley, S John ^a   Logan, Jean ^a   Ding, Yu Shin ^a   Dewey, Stephen L ^a   Hitzemann, Robert ^b   Gifford, Andrew N ^a   Pappas, Naomi R ^a  

^a BROOKHAVEN NATIONAL LABORATORY   (United States)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE TRANSPORTER; METHYLPHENIDATE;

ADULT; ARTICLE; CORPUS STRIATUM; DOPAMINE UPTAKE; DRUG BRAIN LEVEL; DRUG RECEPTOR BINDING; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; RECEPTOR BLOCKING; RECEPTOR OCCUPANCY; SUBSTANCE ABUSE;

ADULT; AGED; CARRIER PROTEINS; COCAINE; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOPAMINE UPTAKE INHIBITORS; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; METHYLPHENIDATE; MIDDLE AGED; NERVE TISSUE PROTEINS; PERCEPTION; SELF ADMINISTRATION; STREET DRUGS; TOMOGRAPHY, EMISSION-COMPUTED; VISUAL CORTEX;

EID: 0032956021     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Aoyama TN, Kotaki HN, Sawada YN and Iga T (1996) Pharmacokinetics and pharmacodynamics of methylphenidate enantiomers in rats. Psychopharmacology (Berl) 127:117-122.
2. Balster RL and Schuster CR (1973) Fixed-interval schedule of cocaine reinforcement: effects of dose and infusion duration. J Exp Anal Behav 20:119-129.
3. Bergman J, Madras B, Johnson SE and Spealman RD (1989) Effects of cocaine and related drugs in nonhuman primates. III: Self-administration by squirrel monkeys. J Pharmacol Exp Ther 261:150-155.
4. Carrey NJ, Wiggins DM and Milin RP (1996) Pharmacological treatment of psychiatric disorders in children and adolescents: Focus on guidelines for the primary care practitioner. Drugs 51:750-759.
5. De Wit H and Wise RA (1977) Blockade of cocaine reinforcement in rats with the dopamine receptor blocker pimozide, but not with the noradrenergic blockers phentolamine or phenoxybenzamine. Can J Psychol 31:195-203.
6. 11C]d-threo and l-threo methylphenidate in the human and baboon brain. Psychopharmacology 131:71-78.
7. Fischman MW and Foltin RW (1991) Utility of subjective-effects measurements in assessing abuse liability of drugs in humans. Br J Addict 86:1563-1570.
8. Fowler JS, Volkow ND, Wolf AP, Dewey SL, Schlyer DJ, MacGregor R, Hitzemann R, Logan J, Bendriem B, Gatley SJ and Christman D (1989) Mapping cocaine-binding sites in human and baboon brain in vivo. Synapse 4:371-377.
9. 11C]cocaine binding to decreases in synaptic dopamine. Synapse 20:137-144.
10. Gatley SJ, Pan D, Chen R, Chaturvedi G and Ding YS (1996) Affinities of methylphenidate derivatives for dopamine, norepinephrine and serotonin transporters. Life Sci 58:231-239.
11. Goeders NE (1997) A neuroendocrine role in cocaine reinforcement. Psychoneuroendocrinology 22:237-259.
12. Hurd YL and Ungerstedt U (1989) Cocaine: An in vivo microdialysis evaluation of its acute actions on dopamine transmission in rat striatum. Synapse 3:48-54.
13. Izenwasser S, Werling LL and Cox B (1990) Comparison of the effects of cocaine and other inhibitors of dopamine uptake in rat striatum, nucleus accumbens, olfactory tubercle, and medial prefrontal cortex. Brain Res 520:303-309.
14. Johanson CE and Schuster CR (1975) A choice procedure for drug reinforcers: Cocaine and methylphenidate in the rhesus monkey. J Pharmacol Exp Ther 193:676-688.
15. Keen M and MacDermot J (1993) Analysis of Receptors by Radioligand Binding (Wharton J and Polak JM eds) pp 50-51, Oxford Science Publications, Oxford.
16. Klein RG, Abikoff H, Klass E, Ganeles D, Seese LM and Pollack S (1997) Clinical efficacy of methylphenidate in conduct disorder with and without attention deficit hyperactivity disorder. Arch Gen Psychiatry 54:1073-1080.
17. Kleven MS and Koek W (1997) Discriminative stimulus properties of cocaine: Enhancement by β-adrenergic receptor antagonists. Psychopharmacology (Berl) 131: 307-312.
18. 11C-methyl]-(-)cocaine PET studies in human subjects. J Cereb Blood Flow Metab 10:740-747.
19. 11C] raclopride binding in the brain: Model simulations and kinetic analysis of PET data. J Cereb Blood Flow Metab 14:995-1010.
20. Moghaddam B and Bunney BS (1989) Differential effect of cocaine on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens: Comparison to amphetamine. Synapse 4:156-161.
21. National Institute on Drug Abuse, Community Epidemiology Work Group (CEWG) (1995) Epidemiologic Trends in Drug Abuse. Washington DC, DHHS Publication no. (NIH) 95:3988.
22. Nestler EJ (1992) Molecular mechanisms of drug addiction. J Neurosci 12:2439-2450.
23. Parran TV and Jasinski DR (1991) Intravenous methylphenidate abuse: Prototype for prescription drug abuse. Arch Intern Med 151:781-783.
24. Patrick KS, Caldwell RW, Ferris RM and Breese GR (1987) Pharmacology of the enantiomers of threo-methylphenidate. J Pharmacol Exp Ther 241:152-158.
25. Pettit HO, Ettenberg A, Bloom FE and Koob GF (1984) Destruction of dopamine in the nucleus accumbens selectively attenuates cocaine but not heroine self-administration in rats. Psychopharmacology 84:167-173.
26. Pontieri FE, Tanda G, Orzi F and Di Chiara G (1996) Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature 382:255-257.
27. Richardson NR and Roberts DCS (1991) Fluoxetine pretreatment reduces breaking points on a progressive ratio schedule reinforced by intravenous cocaine self-administration in ther rat. Life Sci 49-833-840.
28. Ritz MC, Lamb RJ, Goldberg SR and Kuhar MJ (1987) Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science 237:1219-1223.
29. Roberts DC, Loh EA and Vickers G (1994) Lesions of central serotonin systems affect responding on a progressive ratio schedule reinforced either by intravenous cocaine or by food. Pharmacol Biochem Behav 49:177-182.
30. Rocha BA, Fumagalli F, Gainetdinov RR, Jones SR, Ator R, Giros B, Miller GW and Caron MG (1998) Cocaine self-administration in dopamine-transporter knockout mice. Nat Neurosci 1:132-137
31. Spealman RD (1995) Noradrenergic involvement in the discriminative stimulus effects of cocaine in squirrel monkeys. J Pharmacol Exp Ther 275:53-62.
32. Srinivas NR, Hubbard JW, Quinn D, Korchinski ED and Midha K (1991) Extensive and enantioselective presystemic metabolism of dl-threo-methylphenidate in humans. Prog Neuropsychapharmacol Biol Psychiatry 15:213-220.
33. Sora I, Wichems C, Takahashi N, Li XF, Zeng Z, Revay R, Lesch KP, Murphy DL and Uhl GR (1998) Cocaine reward models: conditioned place preference can be established in dopamine- and in serotonin-transporter knockout mice. Proc Natl Acad Sci USA 95:7699-7704.
34. Tella SR (1996) Possible novel pharmacodynamic action of cocaine: Cardiovascular and behavioral evidence. Pharmacol Biochem Behav 54:343-354.
35. Volkow ND, Ding Y-S, Fowler JS, Wang G-J, Logan J, Gatley SJ, Dewey SL, Ashby C, Lieberman J, Hitzemann R and Wolf AP (1995) Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in human brain. Arch Gen Psychiatry 52:456-463.
36. Volkow ND, Fowler JS, Logan J, Gatley JS, Dewey SL, MacGregor RR, Schlyer DJ, Pappas N, King P and Wolf AP (1995b) Carbon-11-cocaine binding compared at sub-pharmacological and pharmacological doses: A PET study. J Nucl Med 36: 1289-1297.
37. Volkow ND, Fowler JS, Wang G-J, Hitzemann R, Logan J, Schlyer D, Dewey S and Wolf AP (1993) Decreased dopamine D2 receptor availability is associated with reduced frontal metabolism in cocaine abusers. Synapse 14:169-177.
38. Volkow ND, Fowler JS, Wolf AP, Shlyer D, Shiue Chy, Albert R, Dewey SL, Logan J, Bendriem B, Christman D, Hitzemann R and Henn F (1990) Effects of chronic cocaine abuse on postsynaptic dopamine receptors. Am J Psychiatry 147:719-724.
39. Volkow ND, Wang G-J, Fischman MW, Foltin RW, Fowler JS, Abumrad NN, Vitkun S, Logan J, Gatley SJ, Pappas N, Hitzemann R and Shea K (1997a) Relationship between subjective effects of cocaine and dopamine transporter occupancy. Nature 386:827-830.
40. Volkow ND, Wang G-J, Fowler JS, Gatley SJ, Ding Y-S, Logan J, Dewey SL, Hitzemann R and Lieberman J (1996a) Relationship between psychostimulant induced high and dopamine transporter occupancy. Proc Nat Acad Sci USA 93: 10388-10392.
41. Volkow ND, Wang G-J, Fowler JS, Gatley JS, Logan J, Ding Y-S, Hitzemann R and Pappas N (1998) Therapeutic doses of oral methylphenidate induce significant levels of dopamine transporter occupancies in the human brain. Am J Psychiatry 155:1325-1331.
42. Volkow ND, Wang G-J, Fowler JS, Logan J, Angrist B, Hitzemann RJ, Lieberman J and Pappas NS (1997b) Effects of methylphenidate on regional brain glucose metabolism in humans: Relationship to dopamine D2 receptors. Am J Psychiatry 154:50-55.
43. Volkow ND, Wang G-J, Fowler JS, Logan J, Gatley SJ, Hitzemann R, Chen AD and Pappas N (1997c) Decreased striatal dopaminergic responsivity in detoxified cocaine abusers. Nature 386:830-833.
44. Volkow ND, Wang G-J, Gatley SJ, Fowler JS, Ding Y-S, Hitzemann R, Logan J, Wong C and Lieberman J (1996b) Temporal relationships between the pharmacokinetics of methylphenidate in the human brain and its behavioral and cardiovascular effects. Psychopharmacology (Berl) 123:26-33.
45. Wang G-J, Volkow ND, Hitzemann RJ, Wong C, Angrist B, Burr G, Pascani K, Pappas N, Lu A, Cooper T and Lieberman JA (1997) Behavioral and cardiovascular effects of intravenous methylphenidate in normal subjects and cocaine abusers. Eur Addict Res 3:49-54.
46. Wood DM and Emmett-Oglesby MW (1988) Substitution and cross-tolerance profiles of anorectic drugs in rats trained to detect the discriminative stimulus properties of cocaine. Psychopharmacology (Berl) 95:364-368.
47. Woolverton WL (1986) Effects of a D1 and a D2 dopamine antagonist on the self-administration of cocaine and piribedil by rhesus monkeys. Pharmacol Biochem Behav 24:531-535.